Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractFor easy handling and speed of lung diseases diagnostics, approaches based on volatile organic compounds (VOCs), including those emitted by pathogenic microorganisms, are considered but currently require considerable sampling efforts. We tested whether easy-to-handle and fast detection of lung infections is possible using solid-phase microextraction (SPME) of 100 ml of exhaled breath. An analytical procedure for the detection of VOCs from the headspace of epithelial lung cells infected with four human pathogens was developed. The feasibility of this method was tested in a cystic fibrosis (CF) outpatient clinic in vivo. Exhaled breath was extracted by SPME and analyzed by gas chromatography-mass spectrometry (GC-MS). The compositions of VOCs released in the infection model were characteristic for all individual pathogens tested. Exhaled breath of CF patients allowed clear distinction of CF patients and controls by their VOC compositions using multivariate analyses. Interestingly, the major specific VOCs detected in the exhaled breath of infected CF patients in vivo differed from those monitored during bacterial in vitro growth. SPME extraction of VOCs from 100 ml of human breath allowed the distinction between CF patients and healthy probands. Our results highlight the importance of assessing the entire pattern of VOCs instead of selected biomarkers for diagnostic purposes, as well as the need to use clinical samples to identify reliable biomarkers. This study provides the proof-of-concept for the approach using the composition of exhaled VOCs in human breath for the rapid identification of infectious agents in patients with lower respiratory tract infections.
CitationA rapid method for breath analysis in cystic fibrosis patients. 2015, 34 (4):745-51 Eur. J. Clin. Microbiol. Infect. Dis.
AffiliationHelmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany.
JournalEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
The following license files are associated with this item:
- In vitro volatile organic compound profiling using GC×GC-TOFMS to differentiate bacteria associated with lung infections: a proof-of-concept study.
- Authors: Nizio KD, Perrault KA, Troobnikoff AN, Ueland M, Shoma S, Iredell JR, Middleton PG, Forbes SL
- Issue date: 2016 Apr 27
- Exhaled breath profiling using broadband quantum cascade laser-based spectroscopy in healthy children and children with asthma and cystic fibrosis.
- Authors: van Mastrigt E, Reyes-Reyes A, Brand K, Bhattacharya N, Urbach HP, Stubbs AP, de Jongste JC, Pijnenburg MW
- Issue date: 2016 Apr 8
- Quantitative analysis of volatile metabolites released in vitro by bacteria of the genus Stenotrophomonas for identification of breath biomarkers of respiratory infection in cystic fibrosis.
- Authors: Shestivska V, Dryahina K, Nunvář J, Sovová K, Elhottová D, Nemec A, Smith D, Španěl P
- Issue date: 2015 Apr 1
- Relationship between cancer tissue derived and exhaled volatile organic compound from colorectal cancer patients. Preliminary results.
- Authors: De Vietro N, Aresta A, Rotelli MT, Zambonin C, Lippolis C, Picciariello A, Altomare DF
- Issue date: 2020 Feb 20
- On the importance of accurate quantification of individual volatile metabolites in exhaled breath.
- Authors: Smith D, Španěl P
- Issue date: 2017 Nov 1